The Risks Of Surrogacy: Egrifta Faces Twofold Challenge At Advisory Committee

Theratechnologies will need to address FDA's concerns about whether a reduction of patients' visceral abdominal fat produced by the HIV lipodystrophy product has clinical meaning and is worth the risks.